Distal Protection Device Promises Renal Applications, Amor's Study Suggests
This article was originally published in The Gray Sheet
Executive Summary
The relatively low profile and maneuverability of the Medtronic/PercuSurge GuardWire distal protection system outweigh the disadvantages of total distal occlusion in renal angioplasty and stenting procedures, according to Max Amor, MD, chief of the Cardiology Clinic at Polyclinique Essey Les Nancy in France.
You may also be interested in...
Medtronic GuardWire Is First Distal Protection Device To Reach Panel Review
PercuSurge's GuardWire Plus will be the first embolic protection device to undergo FDA panel review Feb. 5 when the Circulatory System Devices Panel evaluates the firm's PMA for saphenous vein graft applications.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.